Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Evolving World Of Breast Cancer Management

Executive Summary

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

You may also be interested in...



Innovation In The Age Of Breast-Conserving Surgery

Medical device and diagnostic companies are developing innovative new products for women with breast cancer designed to facilitate earlier diagnosis, improve diagnostic accuracy, increase surgical precision, and enable the least invasive, most breast-conserving approach to breast cancer surgery. With the number of breast cancer cases in the US projected to increase dramatically by 2030, the success of these technologies depends on their ability to improve cosmetic results and survival rates while lowering overall health care costs.

TiaLinx: Developing The First Non-Contact, Non-Ionizing Scanner To Detect Breast Cancer

With the breast cancer screening population expected to reach almost 250 million by 2018, TiaLinx says its new AR60-A scanner is the first non-contact, high-resolution imaging technology that does not emit ionizing radiation, and is an affordable screening alternative for the 210,000 primary care physicians in the US and significantly more worldwide.

GE Healthcare’s Invenia: Improving Breast Cancer Detection In Dense Breasts

GE Healthcare launched in June the Invenia Automated Breast Ultrasound System (ABUS), the first FDA-approved breast cancer screening option for women with dense breasts.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel